Mantle-cell Lymphoma
30
5
5
16
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
12 trials with published results (40%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
13.3%
4 terminated out of 30 trials
80.0%
-6.5% vs benchmark
7%
2 trials in Phase 3/4
75%
12 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (30)
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Allo HSCT Using RIC for Hematological Diseases
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma